Cablivi (caplacizumab-yhdp) is a prescription medication used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting disorder. It works by targeting and inhibiting the activity of von Willebrand factor, a protein in the blood that is involved in clot formation, thereby helping to prevent the formation of harmful clots. Cablivi is typically used in conjunction with plasma exchange and immunosuppressive therapy to manage this condition. It is administered through an injection and is known for its potential to significantly reduce the time required for platelet counts to return to normal, thereby reducing the risk of complications associated with aTTP. As with any medication, it is important to use Cablivi under the guidance of a healthcare professional to ensure its safe and effective use.